Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Mar 16;8(4):811–827. doi: 10.1080/19420862.2016.1160989

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Author(s). Published with license by Taylor & Francis Group, LLC

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

PMC Copyright notice

Figure 9. — XGFR* in vivo efficacy in human orthotopic MiaPaCa-2 pancreatic carcinoma mouse model. A, Representative example of IGF-1R and EGFR expression in human MiaPaCa-2 pancreatic tumor xenografts grown in SCID mice as detected by immuno-histological staining. B, Tumor weight at termination after treatment with XGFR* and XGFR in comparison to conventional EGFR (cetuximab) and IGF-1R antibodies (AMG479*) and a combination of both antibodies in the orthotopic MiaPaCa-2 pancreatic cancer model in SCID mice. Weekly intraperitoneal treatment with XGFR* or XGFR (20 mg/kg), equimolar EGFR or IGF-1R antibodies (10 mg/kg each) or vehicle control was started 10 d after orthotopic implantation of MiaPaCa-2 tumors. Pancreatic tumor weights and per cent of tumor bearing animals were determined on study day 31 after 3 weeks of treatment (n = 15). Note: Tumor growth could not be monitored during this time due to intra-pancreatic localization of the tumors.